^
Association details:
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical Trail

Excerpt:
...- 3 participants with estrogen receptor-positive, HER2-Negative Advanced Breast Cancer were identified by pathological testing....
Trial ID:
Evidence Level:
Sensitive: D – Preclinical
Title:

The Potent Novel CDK4/6 Inhibitor TQB3616 in Hormone Receptor Positive Breast Cancer: Preclinical Characterization with in vitro and Human Tumor Xenograft Models

Published date:
12/08/2023
Excerpt:
TQB3616 showed a remarkable inhibitory effect on the proliferation of hormone receptor-positive breast cancer cells in vitro. In addition, TQB3616 combined with endocrine therapy or Human Epidermal Growth Factor Receptor 2 (HER2) targeted therapy showed significant synergistic antitumor activity in estrogen receptor (ER)-positive/HER2-negative or HER2-positive breast cancer.
Secondary therapy:
HER2 inhibitor; Hormone Therapy
DOI:
https://doi.org/10.2147/BCTT.S434973